Literature DB >> 26071020

Glucose regulates amyloid β production via AMPK.

Ting-Ting Yang1, Yao-Shan Shih2, Yun-Wen Chen3,4, Yu-Min Kuo2,4, Chu-Wan Lee5,6.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia in the elderly. Accumulation of Aβ peptides in the brain has been suggested as the cause of AD (amyloid cascade hypothesis); however, the mechanism for the abnormal accumulation of Aβ in the brains of AD patients remains unclear. A plethora of evidence has emerged to support a link between metabolic disorders and AD. This study was designed to examine the relationship between energy status and Aβ production. Neuro 2a neuroblastoma cells overexpressing human amyloid precursor protein 695 (APP cells) were cultured in media containing different concentrations of glucose and agonist or antagonist of AMP-activated-protein-kinase (AMPK), a metabolic master sensor. The results showed that concentrations of glucose in the culture media were negatively associated with the activation statuses of AMPK in APP cells, but positively correlated with the levels of secreted Aβ. Modulating AMPK activities affected the production of Aβ. If APP cells were cultured in high glucose medium (i.e., AMPK was inactive), stimulation of AMPK activity decreased the production levels of Aβ. On the contrary, if APP cells were incubated in medium containing no glucose (i.e., AMPK was activated), inhibition of AMPK activity largely increased Aβ production. As AMPK activation is a common defect in metabolic abnormalities, our study supports the premise that metabolic disorders may aggravate AD pathogenesis.

Entities:  

Keywords:  AMP-activated-protein-kinase; Alzheimer’s disease; Aβ; Glucose

Mesh:

Substances:

Year:  2015        PMID: 26071020     DOI: 10.1007/s00702-015-1413-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  57 in total

1.  Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study.

Authors:  Rachel A Whitmer; Erica P Gunderson; Elizabeth Barrett-Connor; Charles P Quesenberry; Kristine Yaffe
Journal:  BMJ       Date:  2005-04-29

2.  Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR.

Authors:  R R Russell; R Bergeron; G I Shulman; L H Young
Journal:  Am J Physiol       Date:  1999-08

Review 3.  Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging.

Authors:  Claude Messier
Journal:  Neurobiol Aging       Date:  2005-10-19       Impact factor: 4.673

Review 4.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

5.  AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism.

Authors:  Valérie Vingtdeux; Luca Giliberto; Haitian Zhao; Pallavi Chandakkar; Qingli Wu; James E Simon; Elsa M Janle; Jessica Lobo; Mario G Ferruzzi; Peter Davies; Philippe Marambaud
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

Review 6.  Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy.

Authors:  Chen-Chen Tan; Jin-Tai Yu; Meng-Shan Tan; Teng Jiang; Xi-Chen Zhu; Lan Tan
Journal:  Neurobiol Aging       Date:  2013-11-28       Impact factor: 4.673

7.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function.

Authors:  Zoe Arvanitakis; Robert S Wilson; Julia L Bienias; Denis A Evans; David A Bennett
Journal:  Arch Neurol       Date:  2004-05

Review 8.  Glucose metabolism and insulin receptor signal transduction in Alzheimer disease.

Authors:  Siegfried Hoyer
Journal:  Eur J Pharmacol       Date:  2004-04-19       Impact factor: 4.432

9.  Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease.

Authors:  Ying Liu; Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong
Journal:  FEBS Lett       Date:  2008-01-02       Impact factor: 4.124

10.  Structure of mammalian AMPK and its regulation by ADP.

Authors:  Bing Xiao; Matthew J Sanders; Elizabeth Underwood; Richard Heath; Faith V Mayer; David Carmena; Chun Jing; Philip A Walker; John F Eccleston; Lesley F Haire; Peter Saiu; Steven A Howell; Rein Aasland; Stephen R Martin; David Carling; Steven J Gamblin
Journal:  Nature       Date:  2011-03-13       Impact factor: 49.962

View more
  4 in total

Review 1.  Sirtuins-Mediated System-Level Regulation of Mammalian Tissues at the Interface between Metabolism and Cell Cycle: A Systematic Review.

Authors:  Parcival Maissan; Eva J Mooij; Matteo Barberis
Journal:  Biology (Basel)       Date:  2021-03-04

2.  AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo.

Authors:  Manon Domise; Sébastien Didier; Claudia Marinangeli; Haitian Zhao; Pallavi Chandakkar; Luc Buée; Benoit Viollet; Peter Davies; Philippe Marambaud; Valérie Vingtdeux
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379

3.  SIRT3 activator Honokiol attenuates β-Amyloid by modulating amyloidogenic pathway.

Authors:  Sindhu Ramesh; Manoj Govindarajulu; Tyler Lynd; Gwyneth Briggs; Danielle Adamek; Ellery Jones; Jake Heiner; Mohammed Majrashi; Timothy Moore; Rajesh Amin; Vishnu Suppiramaniam; Muralikrishnan Dhanasekaran
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

Review 4.  The Bewildering Effect of AMPK Activators in Alzheimer's Disease: Review of the Current Evidence.

Authors:  Brhane Teklebrhan Assefa; Gebrehiwot Gebremedhin Tafere; Dawit Zewdu Wondafrash; Meles Tekie Gidey
Journal:  Biomed Res Int       Date:  2020-02-18       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.